$GNPX Collaborators Report Positive Preclinical Data

AUSTIN, Texas & CAMBRIDGE, Mass.

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, reported that its collaborators from The University of Texas MD Anderson Cancer Center (“MD Anderson”) presented positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody, pembrolizumab, for the treatment of lung cancer in a poster presented at the American Association of Cancer Research Meeting 2019. The TUSC2 gene is a tumor suppressor gene, the active agent in Genprex’s Oncoprex™ immunogene therapy.

The poster, entitled “Development of an improved humanized patient-derived xenograft, Hu-PDX, mouse model for evaluation of antitumor immune response in lung cancer” showed that TUSC2 combined with checkpoint blockade was more effective than checkpoint blockade alone in increasing the survival of mice with human immune cells (humanized mice) that had metastatic lung cancer. The TUSC2 treatment with the checkpoint inhibitor pembrolizumab slowed tumor growth significantly. Pembrolizumab previously had no effect on tumor growth in non-humanized mice. The data also demonstrated the Hu-PDX model as an improved platform for evaluation of immunotherapy.

“This sophisticated model gets one step closer to recapitulating certain functions of the human immune response within a manageable scientific animal model and allows us to further test our hypotheses of how a more complex immune system could interact with aggressive cancers when primed by drugs, such as Oncoprex, in humans,” said Julien L. Pham, MD, MPH, President and Chief Operating Officer of Genprex. “These data further support and solidify existing preclinical data showing that Oncoprex immunogene therapy is synergistic with anti-PD1 therapy and could result in a stronger antitumor response compared to either agent alone. It also demonstrates how Oncoprex could be used in combination with other immunotherapies as a viable treatment option for late-stage non-small cell lung cancer.”

Poster Presentation Details:

Date/Time: Wednesday, April 3, 2019 from 8 a.m. to 12 p.m. ET
Location: Georgia World Congress Center, Exhibit Hall B
Session: Immunomodulators and Response to Therapy
Title: Development of an improved humanized patient-derived xenograft, Hu-PDX, mouse model for evaluation of antitumor immune response in lung cancer
Authors: Ismail M. Meraz, Mourad Majidi, Feng Meng, RuPing Shao, Min Jin Ha, Shinya Neri, Bingliang Fang, Steven H. Lin, Peggy T. Tinkey, Elizabeth J. Shpall, Jeffrey Morris, Jack A. Roth. UT MD Anderson Cancer Ctr., Houston, TX

Following the AACR annual meeting, the poster will also be made available on Genprex’s website at genprex.com.

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. Visit the company’s web site at www.genprex.com or follow Genprex on Twitter at twitter.com/genprex, Facebook at facebook.com/genprexinc, and LinkedIn at linkedin.com/company/genprex.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effects of Oncoprex, or Oncoprex in combination with immunotherapies, on cancer. Risks and uncertainties associated with Genprex and its lead product candidate Oncoprex are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

$GGBXF Florida Moves to Regulate Potency of Smokable Medical Cannabis

$PBIO Uptick Newswire Hosts Dr. Bradford A. Young

PHOENIX, AZ / April 8, 2019 / Uptick Newswire recently welcomed Dr. Bradford A. Young, Senior Vice President and Chief Commercial Officer of Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or “the Company”) to The Stock Day Podcast. PBI is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. The interview was hosted by Mr. Everett Jolly.

To begin the interview, Mr. Jolly asked Dr. Young what makes the Company’s Ultra Shear Technology (UST) platform one of the most effective methods known when it comes to mixing CBD oil and water. Dr. Young explained that the UST platform combines the use of ultra-high pressure and intense shear forces to reduce oil drops to such small sizes that they effectively dissolve in water using their proprietary platform. Meanwhile, other competitors have severe limitations.

Dr. Young further explained that since humans are made primarily of water, our bodies have difficulty absorbing oil efficiently. To help address this absorption problem, the Company created its proprietary UST platform, which allows for the creation of stable nanoemulsions that can be better absorbed by the human body and that have a much longer shelf-life.

Mr. Jolly then noted the massive potential of the CBD industry and asked Dr. Young about the Company’s next steps. Dr. Young commented that the CBD oil and CBD-infused beverage markets represent an enormous value, and the Company’s technology will allow players in the field to create more effective and higher quality products. “We’re really excited about using our technology to help manufacturers make better, high-quality products that allow them to have a superior product and a superior delivery mechanism,” stated Dr. Young.

Currently, the Company is in discussions with leading industry providers to create strategic partnerships where they would have access to the UST platform. Through these partnerships, the Company would also help the providers with formulation and process manufacturing so that the products they develop would be of the highest quality on the market.

Mr. Jolly then asked about the Company’s plans for commercializing their UST platform, as well as the other market segments they will explore. Dr. Young explained that the Company plans to both sell their machinery and provide licenses. They are looking to work with the leading providers in the industry to ensure that consumers are receiving the best products available on the market. In terms of other market segments, the UST platform can be used in numerous additional markets including the pharmaceutical, cosmetic and topicals, and food and beverage industries.

Mr. Jolly then asked if the Company is working on any new technologies. Dr. Young explained that the Company is working on several exciting developments, including the refolding of proteins to a more active state which could be useful in biotherapeutics, as well as other advancements in their life sciences technologies.

To close the interview, Dr. Young shared that it is a very exciting time for the Company, as they are beginning to work with strategic partners on the commercialization of their proprietary technologies, including the UST platform and their “BaroFold” protein refolding platform. Dr. Young further shared that the proprietary platforms offered by the Company have been well-received by leaders in the industry due to the advanced solutions they offer and benefits they provide.

New Video Demonstrates Revolution in Soft Drinks, Sports Drinks, and Beer with Vanishing Water-Soluble CBD Oil for Enhanced Quality and Absorption. Click here to view!

https://www.youtube.com/watch?v=gAqFQmsGHcA&feature=youtu.be

To hear Dr. Bradford A. Young’s entire interview, follow the link to the podcast here:

https://upticknewswire.com/featured-interview-coo-brad-young-of-pressure-biosciences-inc-otcqb-pbio/

Investors Hangout is a proud sponsor of “Stock Day”, and Uptick Newswire encourages listeners to visit the company’s message board at https://investorshangout.com/

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of high pressure-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, food science, soil & plant biology, forensics, and counter-bioterror applications. Additionally, PBIO is actively expanding the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the biologics manufacturing and contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

For more information about PBI, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

Investor Contacts:

Richard T. Schumacher, President and CEO (508) 230-1828 (T)

Bradford A. Young, Ph.D., MBA, Sr. VP & Chief Commercial Officer (508) 230-1829 (F)

About Uptick Newswire and the “Stock Day” Podcast

Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets.Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.

602-441-3474

https://upticknewswire.com/

$YGYI Featured in CannabisNewsAudio Publication on Rise of Organic CBD Market

NEW YORK, April 05, 2019 — via CannabisNewsAudio – Youngevity International Inc. (NASDAQ:YGYI) announces the availability of a CannabisNewsAudio Publication titled, “CBD Industry Set to Explode as New Products, Consumers Enter Market.”

To hear the CannabisNewsAudio version, visit: http://cnw.fm/3p5Wc

To read the full editorial, visit: http://cnw.fm/B1lOj

CBD companies that can create good connections with their client bases should be able to grow into this burgeoning market. Recognizing this, Youngevity International Inc. (NASDAQ:YGYI) has made a series of strategic acquisitions that could help establish the company’s position as a leader in 21^st-century cannabis development. The company’s takeover of Khrysos Global netted it a solid supply of organic CBD, as Khrysos has both cannabis cultivation property and facilities to refine CBD oil.

With that backdrop, Youngevity recently launched HempFX to sell its products directly to consumers. For the moment, the company is offering hemp oils. Its product line may increase as additional research and development brings more ideas to market.

About Youngevity International Inc.

Youngevity International Inc., an emerging conglomerate operating in three distinct business segments including a vertically integrated coffee enterprise, a vertically integrated hemp-based product development enterprise including end-to-end processing, and a direct-selling enterprise that consists of an expanding portfolio of consumer brands developed with its in-house product development team and distributed by traditional and nontraditional channels, including a multi-country, direct-selling network. For more information, visit the company’s website at www.YGYI.com.

About CannabisNewsWire (CNW)

CannabisNewsWire (“CNW”) is a specialized information service that (1) aggregates cannabis news, (2) provides CannabisNewsBreaks that quickly updates investors in the space, (3) enhances corporate press releases, (4) helps companies with distribution and optimization of social media, and (5) delivers comprehensive corporate communication solutions. CNW is uniquely positioned in the cannabis market with a strong team of journalists and writers who can help private and public companies reach a wide audience of investors, consumers, journalists and the general public through our ever-growing dissemination network of more than 5,000 key syndication outlets. CNW is bringing unparalleled visibility, recognition and content to the cannabis industry.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications:

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

$NUGS Subsidiaries Carving Out Key Positions within Booming Cannabis Industry

• Job growth in cannabis industry rose 44 percent in 2018, outpacing other sectors in job market
• Subsidiary BudHire uniquely positioned to capitalize on growing need for outsourced personnel solutions
• Legal cannabis spending worldwide expected to increase from $20.1 billion in 2018 to $43.3 billion in 2022 and $63.5 billion in 2024

Cannabis Strategic Ventures Inc. (OTC: NUGS), a Los Angeles-based cannabis firm, is moving swiftly to secure footholds in various sectors of the booming cannabis industry. Economists note that job creation in the cannabis industry is beginning to roll out massive numbers on both the recreational and medicinal sides, with 64,389 new positions added in 2018. That’s a 44 percent increase on the previous year, making it the fastest-growing job sector in the country right now, as an article in Forbes points out (http://nnw.fm/kMjj2).

Supporting this rapidly growing industry is the prime strategy of Cannabis Strategic Ventures. Among the company’s subsidiaries is the aptly-named BudHire, an outsourced employment service specifically designed to…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to NUGS are available in the company’s newsroom at http://nnw.fm/NUGS

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$LXRP $LXX DehydraTECH Technology Revolutionizes CBD Delivery

$TGODF $TGOD Strengthens Commitment to Clean Cannabis Production, Additional Organic Cert.

$TCAN Closes C$16 Million Brokered Private Placement

$GGBXF CBD Infused Product Companies Look To “Go Where The Consumers Already Are”

Palm Beach, FL – April 4, 2019 – Willie Sutton, the infamous bank robber, when he was asked why he robbed banks, answered: “… because that’s where the money is.” Today, smart marketers are “going where the money is” in the infused product markets. A recent report from respected industry researcher, Brightfield brought Sutton’s observations into the 21^st century infused product marketing strategies. It said: ““How many adults do you know who eat gummy bears?” said Paul. “When you go out with friends, what do you do? You drink something.” Imagine you’re at your closest friend’s house to unwind after work one afternoon, and she asks you what you’d rather drink —a glass of rosé, or herbal tea infused with whole plant cannabis. Or you’re running late for work, and realize you forgot to take your dose of cannabinoids. Rather than rub your achy shoulder all day, you sip your morning cannabis-infused coffee during a meeting, knowing the discreet drink will get you ready to take on the day.  Seem a bit far-fetched? Not to emerging cannabis manufacturers who are reimagining the industry. Morning coffee, going for a beer with friends—these are the everyday adult rituals cannabis drinks manufacturers are elbowing their way into. Cannabis-infused drinks are one of 19 distinct subcategories of goods that contain marijuana flower or extracts from it, with a 2017 market value of $163 million. Brightfield Group projects drinks sales will grow by more than 250% by 2021—double the growth rate of flower itself. In addition to coffee and tea, cannabis can be found in sodas, energy drinks and shots, lemonade, punch, and everything in between. Coffee drinks, sans cannabis, are already a $37 billion-dollar industry in the US, and now marijuana manufacturers are aiming to get in on the game.   Active companies in the industry making moves to ready that include:  IONIC Brands Corp., (CSE: IONC), SLANG Worldwide Inc. (CSE: SLNG) (OTC: SLGWF), Plus Products Inc. (CSE:PLUS) (OTC: PLPRF),  Canopy Growth Corporation (NYSE: CGC) (TSX: WEED: TO), Green Growth Brands Inc. (OTC: GGBXF) (CSE: GGB).

Coffee and tea are outliers in the edibles industry—which is dominated by baked goods, chocolate, candy, sugary drinks, and salty snacks—in terms of being low calorie and low sugar. There is already a sizeable niche of cannabis consumers who are health-conscious, want quality ingredients, research their products well, and—good news for product manufacturers—greatly outspend other user segments, as Brightfield Group discovered in recent consumer surveys.

IONIC Brands Corp., (CSE: IONC) BREAKING NEWS:  IONIC Brands is pleased to announce that the Company is advancing into the cannabis-infused beverage market with two highly sought-after coffee patents.

IONIC BRANDS is entering into the infused beverage market with secured patents in the single-serve coffee and beverage pod market. CEO John Gorst states “single–cup coffee is a +$4.5 billion market and the National Coffee Association has estimated more than 40% of Americans own a single-cup coffee maker.  Securing these patents is a great foundation for IONIC BRANDS to enter into the cannabis-infused beverage industry and is complementary to our current premium luxury Cannabinoid products. We also see substantial development potential of new revenue streams through licensing infused coffee and tea brand partnerships.”

As recently announced on April 2, 2019, the patents position IONIC BRANDS to exclusively benefit from patented technology and provide strategic intellectual assets in the cannabis-infused beverage market, which is anticipated to keep pace or exceed other edible markets. The patents (62/037,827 & 15/837,623) are among the first cannabis patents in US history. These exclusive patents are for brewing cannabis infused coffee, tea and cocoa from CannaCafe which are granted in the US only.  Cowen and Company recently released a report in which it pinpoints Starbucks as the likely first major chain that will market products featuring cannabinoids (CBD).  Arcview Market Research indicates that “the consumer appeal is propelling concentrates toward an estimated $8 billion in retail sales by 2022, outpacing growth in traditional flower sales.”

The original method patent was filed in August 2014 and issued on December of 2017. Since then Imbue LLC, CannaCafe’s parent company, has been granted approval for two additional utility patents, one for cannabis coffee, and the other for cannabis tea. The applications cover all commercial based extraction methods including but not limited to CO2, ethanol, and heat. Their ISO certified product is tasteless, 100% water soluble, and includes known cannabinoids such as THC and CBD.    Read this entire announcement  for IONC at:     https://www.financialnewsmedia.com/news-ionc/ 

Additional industry related developments from around the markets:

Plus Products Inc. (CSE:PLUS) (OTCQB: PLPRF) recently announced that Jon Paul, a veteran senior corporate finance executive and certified public accountant, has been appointed as PLUS’ Chief Financial Officer reporting to PLUS co-founder and CEO Jake Heimark. The Company also announces that Craig Heimark has resigned as the Chief Financial Officer effective immediately and has been appointed as the Chief Strategy Officer, and will remain as Chairman, Secretary and a Director.

“Jon has more than 30 years of experience in senior financial management, including roles as CFO and senior financial consultant at both private and public companies across a number of industries including consumer products, health care, and telecom,” said Jake Heimark, PLUS CEO. “When we were recruiting for a senior financial advisor, we met Jon and knew he was the right person to help PLUS develop a disciplined global financial strategy, robust systems and procedures and a strong balance sheet as we scale our business.”

Canopy Growth Corporation (TSX: WEED.TO) (NYSE: CGC) recently welcomed Houseplant, a new brand of Canadian cannabis, to the Canopy Growth family today. Founded by Seth Rogen and Evan Goldberg , Houseplant represents years of product expertise and an unmatched attention to detail within each strain that has been carefully selected and grown.

Commitment to cannabis quality begins with selecting the best genetics and doesn’t stop until the customer opens the jar. Canopy Growth has witnessed how carefully Houseplant has chosen each component of their offering to deliver the highest quality product to Canadians.

SLANG Worldwide Inc. (CSE: SLNG) (OTCPK: SLGWF) last month launched its Reserve product line in the California market. Reserve further extends the O.penVape brand and complements Slang’s existing product line. The new product offering was created in direct response to demand in the market for a curated selection of top strains. Innovative formulations and market-leading prices are at the core of Reserve, adding to an already robust product catalogue. This catalogue has made O.penVape the No. 2 best-selling cannabis brand in the United States since 2014, as reported by BDS Analytics.

As one of the largest cannabis markets in the United States, with recreational sales of $1.2-billion in 2018 per BDS Analytics, California is among Slang’s top-grossing territories. Reserve is sold alongside Slang’s other offerings like Bakked, California’s No. 1 best-selling distillate, and District Edibles, California’s third-best-selling gummy brand, reported by BDS Analytics. Presale orders for Reserve sold out across the state, supporting Slang’s view that a competitively priced vaporizer cartridge will prove to be an essential piece of the California retail cannabis environment.

Green Growth Brands Inc. (OTCQB: GGBXF) (CSE: GGB) recently announced the opening of  its newest Seventh Sense Botanical Therapy CBD shop today at Mayfair Mall in Greater Milwaukee, a Brookfield Properties center. This new location represents the sixth Seventh Sense Shop to open in the United States.

“Mayfair Mall is the premier mall in Greater Milwaukee and we look forward to bringing a remarkable CBD store experience to new customers in the region,” said Peter Horvath, CEO of Green Growth Brands. “Physical shops are our strongest marketing assets, and our presence in the new location will drive hundreds-of-thousands impressions with consumers. As we gear-up to open over 100 CBD shops by mid-summer we are pleased with early signs of conversion, repeat purchases and building engagement with our current shops and online with ShopSeventhSense.com.”

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated forty six hundred dollars for news coverage of the current press release issued above by IONIC Brands Corp. by a non affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email:  editor@financialnewsmedia.com – +1(561)325-8757

$TCAN Closes CDN$16 Million Brokered Private Placement of Units

Vancouver, BC, April 04, 2019 — TransCanna Holdings Inc. (CSE: TCAN, XETR: TH8) (“TransCanna” or the “Company”) is pleased to announce that it has closed its previously announced and upsized brokered private placement of units, generating aggregate gross proceeds of CDN$16.0 million.

An aggregate of 8,000,000 units of the Company (the “Units”) were sold at a price of CDN$2.00 per Unit (the “Offering”).  The Offering was conducted by a syndicate of agents co-led by Haywood Securities Inc. and Canaccord Genuity Corp., and including Gravitas Securities Inc. (collectively the “Agents”)

Each Unit comprised one common share of the Company (each a “Share”) and one half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder to acquire an additional Share at a price of $3.00 until April 4, 2022. The Warrants are issued pursuant to a warrant indenture dated April 4, 2019 between the Company and its warrant agent, Odyssey Trust Company. A copy of the warrant indenture is available under the Company’s profile on SEDAR at www.sedar.com. The Company has agreed to seek a listing of the Warrants on the CSE at such time as all applicable resale restrictions have lapsed, subject to receipt of listing approval.

A commission of 8.0% of the gross proceeds of the Offering was paid partly through the payment of $576,668 in cash and in part through the issuance of 351,666 Units, as well as a corporate finance fee of $250,000, plus applicable taxes, of which $125,000 was paid in cash and the remaining $125,000 was paid through the issuance of 62,500 Units.  In addition, the Agents received an aggregate of 640,000 non-transferable compensation options to acquire up to 640,000 Shares at a price of $2.00 per Share until April 4, 2022.

The Company intends to use the net proceeds of the Offering to fund a US$8.0 million down payment for its proposed acquisition of the 196,000 sq ft cannabis facility as announced on February 4, 2019, for further equipment purchases and for working capital and general corporate purposes. The Company anticipates the completion of the facility acquisition to occur within the next three business days and will provide a further update at that time.

All securities issued pursuant to the Offering are subject to a four month hold period expiring August 5, 2019 in accordance with applicable Canadian securities laws.

For further information, please visit the Company’s website at www.transcanna.com.

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a Canadian-based company focused on providing integrated branding, transportation and distribution services, through its wholly-owned California subsidiaries, to a range of industries including the cannabis marketplace.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at info@transcanna.com.

Media Contact
TransCanna@talkshopmedia.com
604-738-2220

On behalf of the Board of Directors

James Pakulis
Chief Executive Officer

Telephone: (604) 609-6199

The information in this news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Forward-looking statements in this news release include, but are not limited to:  the anticipated timing of the closing of the facility acquisition and the use of proceeds from the financing. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

$VVCIF Canada Prepares for 420

Canada Prepares for 420: Canadian Cannabis Companies Establishing an Online Presence

The Click & Collect service allows age-verified adult-use cannabis consumers to reserve cannabis and accessory products for pickup at stores across the provinces of Alberta and Saskatchewan. The service was launched as part of the Company’s mission to curate the world of cannabis for its customers who seek a more convenient and informative buying experience. Certain cannabis products sell out rapidly, and the Click & Collect service ensures customers are able to reserve high-demand products and receive priority service when visiting a store.

“The Click & Collect service has been adopted very favourably, particularly by our loyal customers using mobile devices,” shared Trevor Fencott, Fire & Flower’s Chief Executive Officer. “We are seeing rapid and continuous growth in use of our Click & Collect service across the entire Fire & Flower retail network.”

Organigram Holdings Inc. (TSXV: OGI) (OTC: OGRMF), the parent company of Organigram Inc., a leading licensed producer of cannabis is also taking full advantage of online capabilities, having announced the release of a cross-platform, patient-focused mobile application.

The Application is designed to offer patients greater convenience in optimizing their medication regimen and stay up-to-date on products, programs and company news. Through this new Application, registered patients are able to: order medical cannabis products and accessories, manage their patient profile, view past orders and order limits, read the latest Organigram news and press releases and communicate with Client Care representatives.

“When it comes to managing their medication, patients have indicated to us that convenience and ease are important to them. This new tool gives patients greater ease of control over their wellness plans,” says Organigram CEO, Greg Engel.

VIVO Cannabis Inc. (TSX-V: VIVO) (OTCQX: VVCIF), through its wholly-owned subsidiary, Canna Farms Limited, has also announced the launch of their own online resource with Canna Farms’ integrated online medical cannabis website.

“Canna Farms’ integrated online store will cater to discerning medical cannabis consumers,” said Daniel Laflamme, President of Canna Farms. “In addition to offering award-winning Canna Farms and Beacon Medical brands, the site will serve as a marketplace for products from other licensed producers who share VIVO’s commitment to delivering premium products and services focused on health and wellness.”

The fact that so many cannabis sales companies are combining brick and mortar and online “grab and go” options falls in line with current global retail trends. Gone are the days of “just online” or “just retail” sales and we see this strongly evidenced with large scale companies like Walmart and Amazon, the online retailer who has now begun opening brick and mortar stores. As Canada readies itself for 420, companies merging the digital and physical sides of their business will certainly stand a higher chance of success at capturing sales.

Read part one of the series:
https://www.investorideas.com/news/2019/cannabis/04031Stocks-Canada.asp

For investors following cannabis stocks, Investor Ideas has created a stock directory of publicly traded CSE, TSX, TSXV, OTC, NASDAQ, NYSE, ASX Marijuana/Hemp Stocks

About Investorideas.com
https://www.investorideas.com/About/

Follow us on Cannabis Social Media
https://www.facebook.com/Investorideaspotcasts/
https://twitter.com/MJInvestorIdeas
https://www.instagram.com/potcasts_investorideas/

Disclaimer/Disclosure: Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp. Disclosure: this article featuring Westleaf (TSX-V: WL) (OTCQB: WSLFF) is a paid for service on Investorideas.com.  Learn more about costs and our services https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country.

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Contact Investorideas.com
800-665-0411

$RIV $RIV.V $CNPOF 420 with CNW – Demand for Medical Cannabis Skyrockets on Rhode Island

$YGYI Khrysos Industries Lands CBD Supply Contract Worth $11 Million

• Youngevity International is a multi-faceted lifestyle company that is rapidly increasing its hemp-based cannabidiol oil production for varied industries
• Youngevity subsidiary Khrysos Global has inked a contract to provide 50 percent of its capacity for 99 percent pure cannabidiol oil, with additional contracts anticipated
• Cannabidiol-infused beverages are gaining traction in the emerging cannabis industry, with anticipated revenue potential between $900 million and $4.4 billion by 2024
• Youngevity’s HempFX and CLR Roasters brands will begin selling cannabidiol-infused coffees next month, and the company is working on another cannabidiol drink under an agreement with Icelandic Glacial bottled water

Multi-faceted and flexibly-oriented lifestyle company Youngevity International Inc. (NASDAQ: YGYI) is expanding its operations in the cannabis industry following the announcement that its subsidiary, Khrysos Global, has entered a contract to produce 99 percent pure cannabidiol oil from hemp that’s free of the psychedelic tetrahydrocannabinol (THC) found in cannabis’ marijuana strains.

The one-year supply and processing agreement is expected to begin with shipments this month and continue in equal amounts through March 2020, amounting to what Khrysos President Dwayne Dundore described as 50 percent of the company’s production capacity utilizing its…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to YGYI are available in the company’s newsroom at http://nnw.fm/YGYI

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$YGYI CBD Industry Set to Explode as New Products, Consumers Enter Market

$TGODF $TGOD Partners with Valens GroWorks, Anticipates Early Market Entry

• Multi-year extraction services agreement with Valens GroWorks Corp. expected to accelerate TGOD’s Canadian hemp strategy and market entry
• TGOD is committed to producing premium, certified organic, consumer-preferred products
• Production strategy calls for 80,000 kg of cultivation by end of 2019

Cannabis-focused research and development company The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) is moving quickly to take advantage of Canada’s nascent legal cannabis market, which is expected to include CBD-infused products by October 2019. TGOD’s recently announced entry into a multiyear extraction services contract with Valens GroWorks Corp. (CSE: VGW) (OTCQB: VGWCF) underscores the company’s focus on meeting a growing need to furnish high-quality, premium organic cannabis products to Canadian consumers, according to a news release (http://nnw.fm/MnI90).

“The ability to partner with skilled and specialized extraction operators such as Valens will add significant bench strength to TGOD’s already robust extraction capabilities in Canada, Poland and Jamaica,” Brian Athaide, director and CEO of TGOD, stated in a…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://nnw.fm/TGODF

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$GGBXF Five Stocks to Watch as Legal Marijuana Evolves

CORAL GABLES, FL / April 2, 2019 / The marijuana stock market has been booming over the course of the past few years as a result of the sheer excitement surrounding the cannabis industry. Any investor who paid attention to the cannabis sector knows that companies responsible for growing cannabis have always rested at the top of the market. While producing cannabis is important for the industry, this completely overlooks the potential opportunities in investing in ancillary businesses operating within the sector. These cannabis companies are working to innovate the operational processes in order to make a better and more effective product for the marijuana industry. Nabis Holdings (INNPF) (NAB), Starbucks Corporation (SBUX), Green Growth Brands Inc (OTCQB: GGBXF), Cresco Labs Inc (OTCQX: CRLBF), and Cronos Group Inc (NASDAQ: CRON, TSX: CRON) are 5 stocks worth keeping track of as the cannabis industry continues to evolve.

Nabis Holdings (INNPF) (NAB) is a Canadian investment company laser-focused on making key investments in high-quality cash flowing assets across all aspects of the cannabis sector mainly in U.S. limited license states. The company has a keen sense for identifying and acquiring a majority stake in cannabis brands and assets to generate high-quality cash flows.

Nabis Holdings (INNPF) (NAB) dominated headlines last month when the Company announced that it has entered into a revised agreement, co-led by Canaccord Genuity Corp. and Eventus Capital Corp., to increase the size of its previously announced amended brokered private placement of debenture units to raise gross proceeds of up to C$35,000,000.

Per the details of the agreement, the Company has increased the Agents’ option, exercisable at any time up until 48 hours prior to the Closing Date, to arrange for the sale of additional Debenture Units for additional aggregate gross proceeds to the Company of up to C$10,000,000. If the Over-Allotment Option is exercised in full, the aggregate gross proceeds of the Amended Offering will be C$45,000,000. The Company plans on using the net proceeds of the offering to fund cannabis related investments, for strategic investment opportunities and for general working capital purposes.

For More Information On Nabis Holdings, Click Here

Starbucks Corporation (SBUX) announced back in March that the Company would be holding its 27th Annual Meeting of Shareholders, with nearly 4,000 shareholders, partners, invited guests and board members in attendance. Per the details at the time, key presenters included Kevin Johnson, president, and chief executive officer of Starbucks; Roz Brewer, Americas group president, and chief operating officer; Patrick Grismer, executive vice president, and chief financial officer; and Michelle Burns, senior vice president of Global Coffee & Tea.

In a press release regarding the meeting, Kevin Johnson, President, and CEO of Starbucks said, ”Starbucks is a different kind of company – and we have been since our founding. Our long-term plan for growth with focus and discipline is built on the acknowledgment that the pursuit of profit is not in conflict with the pursuit of doing good. We are a part of millions of people’s everyday lives around the world, and I believe we are uniquely positioned to be one of the most enduring brands of all time.”

For More Information On Starbucks Corporation, Click Here

Green Growth Brands Inc (GGBXF) announced at the tail-end of March the opening of its newest Seventh Sense Botanical Therapy CBD shop today at Mayfair Mall in Greater Milwaukee, a Brookfield Properties center. This new location represents the sixth Seventh Sense Shop to open in the United States.

Peter Horvath, CEO of Green Growth Brands, stated, ”Mayfair Mall is the premier mall in Greater Milwaukee and we look forward to bringing a remarkable CBD store experience to new customers in the region. Physical shops are our strongest marketing assets, and our presence in the new location will drive hundreds-of-thousands impressions with consumers. As we gear up to open over 100 CBD shops by mid-summer we are pleased with early signs of conversion, repeat purchases and building engagement with our current shops and online with ShopSeventhSense.com.”

For More Information On Green Growth Brands Inc, Click Here

Cresco Labs Inc (CRLBF) and CannaRoyalty Corp. d/b/a Origin House yesterday announced the two companies have entered into a definitive agreement pursuant to which Cresco Labs will acquire all of the issued and outstanding shares of Origin House. Per the details of the transaction, the deal represents a total consideration of approximately C$1.1 billion on a fully-diluted basis, or C$12.68 per Origin House Share, as well as the largest public company acquisition in the history of the U.S. cannabis industry.

Following the announcement, Charlie Bachtell, CEO, and Co-founder of Cresco Labs said, ”the acquisition of Origin House is another example of our focused and disciplined approach to creating a meaningful presence in key cannabis markets through excellence in brand development and distribution. It establishes Cresco Labs as the leading multi-state operator with one of the largest distribution platforms in California, which is projected to be a $7.7 billion cannabis market in 2022 by ArcView Market Research/BDS Analytics.”

For More Information On Cresco Labs Inc, Click Here

Cronos Group Inc (CRON) announced in late-March its financial results for the fourth quarter and full year ended December 31, 2018. Over the course of 2018, Cronos Group became the first pure-play cannabis company to list on a major stock exchange in the United States, and in their fourth quarter, the Company closed the $2.4 billion equity investment made by Altria Group, Inc.

Mike Gorenstein, CEO of Cronos Group, commented, ”we are proud of all we have accomplished in 2018 and in the fourth quarter. Over the past year, Cronos Group has diligently focused on our strategic objectives, which culminated in our transformative partnership with Altria Group, Inc. We’ve expanded our production footprint domestically and internationally, developed our distribution with global partnerships, launched iconic brands for the Canadian adult-use market and grown our IP portfolio with landmark research and development initiatives.”

For More Information On Cronos Group Inc, Click Here

About marijuanastocks.com

MarijuanaStocks.com is the leading web destination for all things cannabis. Investors can find marijuana-related financial, medical, legal, and social news anytime day or night. Writers are invited to submit cannabis related articles for publication.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. MAPH Enterprises LLC which owns www.MarijuanaStocks.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC (owners of MarijuanaStocks.com), Midam Ventures LLC and Nabis Holdings (OTC:INNPF) (CSE:NAB), Midam has been paid $250,000 by Nabis Holdings (OTC:INNPF) (CSE:NAB) for a period from January 22, 2019 to April 22, 2019. We may buy or sell additional shares of (OTC: INNPF) (CSE: NAB) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Nabis Holdings (OTC: INNPF) (CSE: NAB). Click here for our full disclaimer.

$TGODF $TGOD 420 with CNW – Colorado House Bill Could Legalize Marijuana Lounges

$TGODF $TGOD Receives Second Organic Certification; Gains Initial Approval on Hamilton Facility

• TGOD recently received its second organic certification at its Hamilton facility
• Jefferies and Seaport Global have initiated coverage on the company’s stock
• TGOD’s Canada-listed shares climbed by more than 19 percent between February 28 and March 28, 2019
• Company has received initial approval to operate a cannabis greenhouse in Ancaster, Ontario

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) is now most definitely on the radar of the investment community. In February, NYC-based investment bank Jefferies initiated coverage of the stock with a ‘Buy’ recommendation (http://nnw.fm/wC4Lm). The company’s stock price has been climbing in the wake of this milestone. Coverage appears to have increased investor confidence, as has confirmation that the company continues to pursue its strategy of producing premium organic cannabis at low cost. TGOD has received organic certification from Pro-Cert Organic Systems Ltd. for its Hamilton facility, the second time it has done so.

Earlier, Seaport Global Securities’ Senior Equity Analyst initiated coverage on the company with a ‘Buy’ rating and a bullish price target, citing the…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://nnw.fm/TGODF

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$GNPX Posts Clinical, Corporate and Financial Update

$PBIO Ultra Shear Platform Key to Future of CBD-Infused Beverages

New Video Demonstrates Revolution in Soft Drinks, Sports Drinks, and Beer with Vanishing Water-Soluble CBD Oil for Enhanced Quality and Absorption

SOUTH EASTON, MA / April 2, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the life sciences and other industries, today released a new, short video demonstrating the ability of the Company’s proprietary Ultra Shear Technology (UST™) platform to create water-soluble CBD oil that disperses instantly, resulting in improved dosing effectiveness, enhanced absorption, and more aesthetically-pleasing products when added to carbonated soft drinks, vitamin-infused sports drinks, and beer.

Link to video: PBI UST CBD Video 040219

In addition to superior aesthetic quality, the Company believes the resulting low nanometer-scale emulsions (“nanoemulsions”) of UST-processed CBD oil should also result in optimized and reproducible bodily absorption, bioavailability, and dosing safety for CBD oil and other UST-processed materials, when compared to many of the processed CBD oils and products that are commercially available today.

Mr. Edgar Ward, President and CEO of NutraLife Biosciences (OTCQB: NLBS), said: “NutraLife manufactures and sells NUTRAHEMPCBD, a line of CBD-infused products that includes creams, sprays, and other products that support daily health and wellness uses. We strive to ensure that our CBD-infused products will always be of the highest quality possible; therefore, we are constantly looking for advanced technologies to continue to improve our manufacturing processes. After reviewing available data and PBI’s videos, we believe methods like PBI’s UST platform may enable us to offer products with superior quality and effectiveness.”

CBD is a non-psychoactive, oil-soluble compound extracted from the cannabis plant, and is typically marketed dissolved in plant oil. It has been widely reported to offer numerous health benefits from stress and anxiety relief, to decreased muscle, joint, cancer and other pain, reduced inflammation, and to nearly miraculous relief of persistent seizures. However, because CBD is an oil-based product, its ingestion typically results in poor absorption in water-based living systems. There has been enormous interest in the development of truly water-soluble CBD, to achieve efficient absorption and bioavailability from foods and beverages. The market for CBD beverages alone could achieve revenue of $260 million in just the U.S. by2022 (Bloomberg, September 27, 2018) and much more world-wide. Unfortunately, because of solubility issues, many CBD products on the market today contain an inefficient over-abundance of CBD and/or undesirable chemicals to improve and stabilize its solubility in water. PBI believes that all of these beverages and other CBD-based products could substantially benefit from PBI’s Ultra Shear Technology platform, to achieve water solubility and stability from the physics of high-pressure shearing – rather than from dependency upon chemistry and reliance upon use of undesirable chemicals.

Dr. Brad Young, Chief Commercial Officer of PBI, commented: “We are very pleased to now show (in this follow-up video) the ability of our proprietary UST platform to mix CBD oil in water and infuse carbonated soft drinks, vitamin-infused sport drinks, and beer. This latest video further highlights the power of our UST platform to make nanoemulsions and its potential to help nutraceutical and beverage manufacturers make high-quality, oil-based products. With such compelling results to rely on, and with numerous opportunities ahead of us, we intend to accelerate the development of our UST platform to better address what we believe are several multi-billion-dollar markets in nutraceuticals, cosmetics, and food & beverages.”

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of high pressure-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, food science, soil & plant biology, forensics, and counter-bioterror applications. Additionally, we are actively expanding the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired protein disaggregation and refolding technology from BaroFold, Inc. to allow entry into the biologics manufacturing and contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (UST™) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward-Looking Statements

This press release contains forward-looking statements. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the Company’s industry results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. These forward-looking statements are made under the ”safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy, and financial needs. These statements are only predictions based on the Company’s current expectations and projections about future events. Investors should not place undue reliance on these statements. In evaluating these statements, Investors should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause the Company’s actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report and other reports filed from time to time with the Securities & Exchange Commission (SEC). More detailed information about these risk factors are set forth in the Company’s filings with the SEC. The Company encourages Investors to review these risk factors. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law. For more information about the Companies, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

Investor Contacts:

Richard T. Schumacher, President and CEO (508) 230-1828 (T)

Bradford A. Young, Ph.D., MBA, SVP and CCO (508) 230-1829 (F)

SOURCE: Pressure BioSciences, Inc.

$YGYI Khrysos Industries, Inks $11 Million Supply Contract

SAN DIEGO, April 1, 2019 — Youngevity International, Inc. (NASDAQ: YGYI), a leading omni-direct lifestyle company, announced today that it executed a one year Supply and Processing Agreement to produce 99% pure CBD (No THC) Isolate. Shipping under the contract is expected to begin this month and continue in equal amounts through March of 2020.

“We are excited to reach the revenue stage for the end to end processing component of our business model. This contract encompasses 50% of our production capacity and we anticipate executing contracts for the balance of our current capacity within the next few months. Due to customer demand we are implementing our plan of increasing our end to end processing capabilities by 10 times in Q3 of this year providing estimated annual revenue potential in excess of $220 million at current market prices,” said Dwayne Dundore, President of Khrysos.

“The Khrysos Industries business model is multi-dimensional, and we are just now starting to fully leverage the capabilities of our extraction systems, end to end processing platform, and the capabilities of INX Labs. We anticipate gearing up our production capabilities across the platform as we move through 2019,” said Dave Briskie, President and CFO of YGYI about its wholly owned subsidiary Khrysos Industries.

About Youngevity International, Inc.
YGYI, Inc. (NASDAQ: YGYI), is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model, that also offers e-commerce and the power of social selling. Assembling a virtual Main Street of products and services under one corporate entity YGYI offers products from the eight top-selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, fashion, essential oils, photo, as well as innovative services. The Company was formed in the course of the summer 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company (now part of the company’s food and beverage division). The resulting company became Youngevity International, Inc. in July 2013. For investor information, please visit YGYI.com. Be sure to like us on Facebook and follow us on Twitter.

To receive future press releases via email, please visit: https://ygyi.com/investors/email-alerts/

Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, and includes statements regarding the expected  shipping timelines for product under the contract, anticipated execution of contracts for the balance of the capacity within the next few months, the anticipated annual revenue potential of the contract in excess of $220 million and the expected increased capacity and capabilities of the extraction technology..  These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, our ability to increase revenue through our extraction technology, increase capabilities and capacity within the timeframes disclosed and execute additional extraction technology contracts, our ability to generate annual revenue from the contract in excess of $220 million, and our ability to increase capacity and capabilities of the extraction technology ,,  our ability to continue our international growth, our ability to continue our coffee segment growth, our ability to leverage our platform and global infrastructure to drive organic growth, our ability  to improve our profitability, expand our liquidity, and strengthen our balance sheet, our ability to continue to maintain compliance with the NASDAQ requirements, the acceptance of the omni-direct approach by our customers, our ability to expand our distribution, our ability to add additional products (whether developed internally or through acquisitions), our ability to continue our financial performance and the other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2017 and our subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Contacts:

Youngevity International, Inc.
Dave Briskie
President and Chief Financial Officer
1 800 982 3189 X6500

Investor Relations
YGYI investor relations
800.504.8650
investors@ygyi.com

Media Contact
Dwain Schenck
Schenck Strategies
203-223-5230
dwain@schenckstrategies.com

$TCAN Announces Closing Date for CDN$16 Million Brokered Private Placement

Vancouver, British Columbia–(April 1, 2019) – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) is pleased to announce that the closing date of the recently announced private placement will be on Thursday, April 4^th, 2019.

“The private placement was oversubscribed, allowing us to bring in a significant number of new investors and materially increase our shareholder base. In fact, the volume of subscriptions caused a slight delay in our original anticipated closing date. With that said, we are extremely thankful to all of the investors who are participating in the private placement,” stated Jim Pakulis, CEO of TransCanna.

As reported in our March 14^th press release, as a result of significant demand, the Company’s brokered private placement of 5,000,000 units of the Company (the “Units”) at a price of CDN$2.00 per Unit (the “Offering”), is oversubscribed. Consequently, the Company increased the size of the Offering by sixty percent to a maximum of 8,000,000 Units to raise gross proceeds of CDN$16,000,000. The terms of the Units under the Offering remain unchanged as previously announced in our March 14^th and February 20^th press releases. The Offering is being conducted by a syndicate of agents co-led by Haywood Securities Inc. and Canaccord Genuity Corp., and including Gravitas Securities Inc.

For further information, please visit the Company’s website at www.transcanna.com.

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a Canadian based company providing branding, transportation and distribution services, through its wholly-owned California subsidiaries, to a range of industries including the cannabis marketplace.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at info@transcanna.com.

Media Contact
TransCanna@talkshopmedia.com
604-738-2220

On behalf of the Board of Directors

James Pakulis
Chief Executive Officer

Telephone: (604) 609-6199

The information in this news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Forward-looking statements in this news release include, but are not limited to: the anticipated timing of the closing of the financing and the expected proceeds therefrom. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

$TGOD $TGODF Analysts are Predicting a 48% Potential Upside Ahead

TGOD stock is selling for $4.82 CAD on the TSX at present. But analysts are watching closely, and an average price target suggests that The Green Organic Dutchman (TSX:TGOD)(OTCQX:TGODF) has potential upside ahead.

TGOD Stock: Is there Upside Ahead?

Unlike many of its peers, TGOD stock has yet to hit a major US exchange such as the NYSE or NASDAQ. As such, trading on the OTCQX in the US can belie this company’s potential. None-the-less, the company’s somewhat different approach to the cannabis industry has made an impression on analysts.

The Green Organic Dutchman is placing focus on the high-end marijuana market or “craft cannabis” market.

According to The Motley Fool:

“The company is aiming at the high end of the marijuana market, touting its organic product line and seeking to maintain premium pricing from customers who are willing to pay up for quality.”

It’s not a bad idea. Focusing on a niche may allow it to be recognized as a brand leader in high-quality cannabis products. A case of quality over quantity perhaps. Artisan and craft culture equates to booming business in foods and alcohol; cannabis may soon be the exact same.

Analyst Opinion

Analysts at Jeffries, Seaport Global, Fundamental Research Group, and Canaccord Genuity are currently watching TGOD stock. According to MJObserver, the average price target set by these four groups is $7.175 CAD per share. Looking at the current price of $4.82 CAD, this represents a potential upside of 48.86% for TGOD stock.

Of course, that’s if these analysts are to be correct.

It’s a very plausible upside if TGOD stock continues its trend, which has seen shares already climb over 80% on a year-to-date basis.

The Grower’s Circle Launch

Most recently, the international cannabis producer has begun shipments of its “certified-organic” medical-grade cannabis for medical patients across Canada. According to the press release “The Growers’ Circle is a select group of patients across Canada now receiving TGOD’s first certified-organic flower.” This launch is a “limited production rollout of the Company’s premium product.” Effectively, TGOD will ramp-up production later this year following this initial run of its exclusive product.

Are you a TGOD stock investor? Do you get excited when analyst consensus shows a significant potential? Or do you take analyst opinion with a pinch of salt?

$NETE Full-Year 2018 Financial Results, Business Update

Miami, Florida–(April 1, 2019) – Net Element, Inc. (NASDAQ: NETE) (“Net Element” or the “Company”), a global technology and value-added solutions group that supports electronic payments acceptance in a multi-channel environment, including point-of-sale (“POS”), e-commerce and mobile devices, today reports financial results for the fiscal year ended Dec. 31, 2018, and provides an update on recent strategic and operational initiatives.

Conference Call

On April 2, 2019, at 8:30 a.m. EST, the Company will host a conference call to discuss 2018 financial results and business highlights. The conference call can be accessed live over the phone by dialing +1 (877) 303-9858, or for international callers +1 (408) 337-0139, and referencing conference code 8437549. It is recommended that participants dial in approximately 10 minutes prior to the start of the call.

The call will also be webcast live from https://edge.media-server.com/m6/p/faqumxh9. Following completion of the call, a recorded replay of the webcast will be available on the www.netelement.com/en/ir website.

2018 Full-Year Financial Highlights

• Total processing volume of $3.3 billion, an increase of 18% compared to $2.8 billion in 2017
• Net revenue of $65.8 million, an increase of 10% compared to $60.1 million in 2017
• Gross margin of $10.2 million, an increase of 15% compared to $8.8 million in 2017
• Operating expenses were $14.5 million, a decrease of 17% compared to $17.4 million in 2017
• Net loss per share decreased to ($1.28) in 2018 compared to net loss per share of ($5.04) in 2017, a decrease of 75%

2018 Significant Achievements

• Acquired recurring cash flow portfolios projected to add over $9 million in gross profits over the next four years.
• Ranked as one of the fastest growing companies in North America on Deloitte’s 2018 Technology Fast 500^TM
• Ranked in the top 10 retail payment consulting/services companies of 2018 by Retail CIO Outlook magazine
• Jon Najarian of CNBC “Halftime Report” and “Fast Money,” and Jonathan Fichman, a fintech and startup executive, joined Net Element’s board of directors
• Net Element subsidiary Unified Payments is among the first companies to achieve self-regulatory certification from the Electronics Transactions Association

“Successful execution of our strategy in 2018 has created a predictable and resilient business model for the company entering 2019,” said Net Element CEO Oleg Firer. “We believe our technology-centered service offerings built around payment ecosystems will continue to differentiate our company as we continue to provide value-added payment solutions to our clients.”

Outlook

Net Element’s strategy is to ensure that our business remains successful in a rapidly changing market, creating sustainable value for all our stakeholders, including our clients, distribution partners and shareholders. We aim to achieve superior results for our clients by having a deep understanding of their payment acceptance needs, along with having extensive market reach, strong product development and technology enablement.

Planned for 2019

We will continue to focus on understanding our clients and addressing their payment acceptance needs in core market segments.

• Continue growth in all key segments and expand our network of referral partners
• Drive and improve client retention
• Expand our client base in selected markets
• Deliver value-added products to our clients to increase efficiencies and payment acceptance
• Launch new tools to reach our clients, such as digital channels, and deepen partner relations

The global payments industry continued to deliver healthy growth during 2018, with underlying transaction volumes demonstrating even greater strength. We believe that new and disruptive technologies will provide us with the opportunity to differentiate ourselves from our competition and to continue developing and delivering innovative payment solutions in 2019 and beyond.

• Continue to scale and enhance Netevia, our future-ready multi-channel payments platform, enabling intelligent routing of payments for the application development community
• Continue to scale and enhance new product launches that will add value for our clients
• Extend our capabilities in next-generation POS hardware and software and deepen our partner proposition
• Continue trials of advanced technologies centered on business intelligence and mobile-based payments acceptance
• Continue the further development of disruptive emerging technologies such as blockchain technologies, enablement of Internet of Things (“IoT”), biometrics payment acceptance and artificial intelligence
• Continue research and investments in future emerging payment technologies

Realize the full potential of our business model.

• Deliver stronger organic growth
• Monetize on acquisitions completed in 2018
• Develop additional payment network relationships to integrate with our technologies
• Seek acquisition or investment opportunities to deepen our technological and distribution capabilities

We continue to believe that disruptive technologies such as blockchain, IoT, biometrics payments and artificial intelligence will play key roles in future commerce. These technologies will encourage innovation through development of value-added services and cater to both merchants and their customers.

We believe Netevia, our future-ready payments platform, will act as a framework and core for a number of value-added services that can connect merchants and consumers directly, utilizing these disruptive technologies while increasing the economic efficiency of all transactions being made within the ecosystem. Specifically, Netevia Payments Platform delivers end-to-end payment processing through easy-to-use APIs and complements the Company’s ability to perform in a multi-channel environment including point-of-sale (POS), e-commerce and mobile devices. Netevia will enable the Company to perform as a hub for disruptive emerging technology solutions.

Results of Operations for the Year Ended Dec. 31, 2018, compared to the Year Ended Dec. 31, 2017

We reported a net loss attributable to common stockholders of approximately $4.9 million or ($1.28) loss per share for the year ended Dec. 31, 2018, as compared to a net loss of approximately $9.9 million or ($5.04) loss per share for the year ended Dec. 31, 2017. This resulted in a decrease in net loss attributable to stockholders of approximately 50%, primarily due to an increase in revenues and other income, decreases in costs related to branded content, combined with selling, general and administrative expenses, and non-cash compensation. This decrease in net loss was partially offset by an increase in bad debt expense.

The following table sets forth our sources of revenues, cost of revenues and gross margins for the years ended Dec. 31, 2018 and Dec. 31, 2017.

Gross Margin Analysis:

Net revenues consist primarily of service fees from transaction processing. Net revenues were approximately $65.8 million for the year ended Dec. 31, 2018, as compared to approximately $60.1 million for the year ended Dec. 31, 2017. The increase in net revenues is primarily due to continued organic growth of North American merchants with emphasis on value-added offerings, and the acquisition of a recurring cash flow portfolio in July 2018. The net increase also is reflective of the following factors which consisted of: A $2 million decrease in net revenues from our International Transaction Solutions segment as we experienced increased competition; reorganized assignments from our International Transaction Solutions segment; and an approximate $1.9 million reduction in gross revenues due to the adoption of ASC 606. For the year ended Dec. 31, 2017, approximately $2.2 million was included in gross revenues that would have been excluded under ASC 606.

Cost of revenues represents direct costs of generating revenues including commissions, mobile operator fees, interchange expense, processing and non-processing fees. Cost of revenues for the year ended Dec. 31, 2018, was approximately $55.6 million as compared to approximately $51.2 million for the year ended Dec. 31, 2017. The increase of approximately $4.4 million in cost of revenues in 2018 as compared to 2017 was primarily driven by the increase in North American Transaction Solutions revenues and expenses associated with new sponsoring bank relationships. An approximate $1.9 million reduction in cost of revenues was due to the adoption of ASC 606 for the year ended Dec. 31, 2018. For the year ended Dec. 31, 2017, approximately $2.2 million was included in costs of revenues that would have been excluded under ASC 606.

Gross margin for the year ended Dec. 31, 2018, was approximately $10.2 million or 15.5% of net revenue, as compared to approximately $8.8 million or 14.7% of net revenue, for the year ended Dec. 31, 2017. This increase in the gross margin percentage was primarily the result of North American Transaction Solutions segment processing of transactions utilizing our self-designated BIN/ICA and further acceptance of value-added services by the merchants.

Total operating expenses were approximately $14.5 million for the year ended Dec. 31, 2018, as compared to total operating expenses of approximately $17.4 million for the year ended Dec. 31, 2017. Total operating expenses for the year ended Dec. 31, 2018, consisted of selling, general and administrative costs of approximately $9.8 million, non-cash compensation of approximately $142,000, bad debt expense of approximately $2.1 million, and depreciation and amortization expense of approximately $2.5 million. For the year ended Dec. 31, 2017, total operating expenses consisted of general and administrative costs of approximately $10.6 million, non-cash compensation of approximately $2.9 million, bad debt expense of approximately $1.3 million, and depreciation and amortization expense of approximately $2.5 million.

Selling, general and administrative expenses for the years ended Dec. 31, 2018, and Dec. 31, 2017, consisted of operating expenses not otherwise delineated in the accompanying audited consolidated statements of operations and comprehensive loss, as follows:

The total decrease of approximately $0.9 million in selling, general and administrative expenses for the year ended Dec. 31, 2018, as compared to the prior year was primarily due to the Company’s continued monitoring of operations and the labor costs necessary to maintain or increase revenues, along with the reorganization of assignments in the International Transaction Solutions segment, which resulted in a decrease of approximately $351,000. These objectives were also responsible for the decrease of approximately $384,000 in professional fees associated with operations.

Professional fees were $2,252,681 for the year ended Dec. 31, 2018, as compared to $2,636,838 for the year ended Dec. 31, 2017, representing a decrease of $384,157 as follows:

Non-cash compensation expense was $142,000 for the year ended Dec. 31, 2018, as compared to approximately $2.9 million for the year ended Dec. 31, 2017. A summary of 2018 and 2017 non-cash compensation activity follows:

2018 Non-Cash Compensation Activity:

2017 Non-Cash Compensation Activity:

Bad Debt Expense:

We reflected a bad debt expense on the accompanying consolidated statements of operations, which represents uncollected fees of approximately $2.1 million for the year ended Dec. 31, 2018, compared to bad debt expense representing uncollected fees of approximately $1.3 million for the year ended Dec. 31, 2017. The increase of approximately $800,000 from the prior year primarily resulted from an increase of approximately 15.6% in gross revenues from our North American Transaction Solutions segment, which in the normal course of business resulted in an increase in net ACH rejects and uncollectible non-processing fees. For the year ended Dec. 31, 2018, total gross ACH rejects equaled approximately $4 million, of which $1.9 million was subsequently collected. We were able to pass through to independent sales organizations (“ISO’s), via a reduction in commissions, $949,000 from the total gross ACH rejects.

For the year ended Dec. 31, 2017, total gross ACH rejects equaled approximately $3.7 million, of which $2.4 million was subsequently collected. We were able to pass through to independent sales organizations, via a reduction in commissions, $603,000 from the total gross ACH rejects.

During the year ended Dec. 31, 2018, approximately $300,000 of the $4 million in gross ACH rejects was attributable to merchant processing losses, while the remaining $3.7 million was related to non- processing fees billed to merchants. Approximately $200,000 of the merchant processing losses was passed on to ISOs. This resulted in net processing losses of $100,000 or .004% of total volume.

During the year ended Dec. 31, 2017, approximately $400,000 of the $3.7 million in gross ACH rejects is attributable to merchant processing losses, while the remaining $3.3 million was related to non- processing fees billed to merchants. Approximately $323,000 of merchant processing losses were passed on to ISOs. This resulted in net processing losses of $101,000 or 0.004% of total volume.

Depreciation and amortization expense consists primarily of the amortization of merchant portfolios in connection with residual buyout arrangements, depreciation expense on equipment, client acquisition costs, capitalized software expenses, trademarks, domain names and employee non-compete agreements. Depreciation and amortization expense was approximately $2.5 million for the years ended Dec. 31, 2018, and Dec. 31, 2017.

Interest expense was approximately $847,000 million for the year ended Dec. 31, 2018, as compared to approximately $1.2 million for the year ended Dec. 31, 2017, representing a decrease of approximately $340,000, primarily due to payoffs of the MBF and RBL notes in the normal course of business.

Other income for the year ended Dec. 31, 2018, of approximately $792,000 consisted primarily of a gain recorded on the transfer of Digital Provider’s net assets to PayOnline (approximately $198,000), net gain in connection with the review and analysis of accounts receivable and accounts payable aging (approximately $856,000), gain on the write-off of TOT Group Russia (approximately $312,000), gain on the reversal of stock price guarantees in connection with the purchase of PayOnline that expired (approximately $313,000), partially offset by costs associated with common stock purchase agreement with ESOUSA Holdings, LLC (approximately $(227,000)), and approximately ($332,000) in miscellaneous other expenses.

Other income and expenses for the year ended Dec. 31, 2017, consisted primarily of approximately $117,000 in foreign taxes and other expenses attributed to our International Transaction Solutions segment, as well as approximately $48,000 in miscellaneous other expenses in the North American Transaction Solutions segment.

The net loss attributable to non-controlling interests amounted to approximately $87,000 and $110,000 for the years ended Dec. 31, 2018, and Dec. 31, 2017, respectively. The loss was attributed to our North American Transaction Solutions segment. representing its 20% non-controlling interest in Aptito. The non-controlling interest reflects the results of operations of subsidiaries that are allocable to minority equity owners.

Reconciliation of Non-GAAP Financial Measures and Regulation G Disclosure

To supplement its consolidated financial statements presented in accordance with United States generally accepted accounting principles (“GAAP”), the Company provides additional measures of its operating results by disclosing its adjusted net loss attributable to Net Element, Inc. stockholders. Adjusted net loss attributable to Net Element, Inc. stockholders is calculated as net loss attributable to Net Element, Inc. stockholders excluding non-cash share-based compensation and other non-operating, non-recurring items. Net Element discloses this amount on an aggregate and per share basis. These measures meet the definition of non-GAAP financial measures. The Company believes that application of these non-GAAP financial measures is appropriate to enhance the understanding by the Company’s investors of its historical performance through use of a metric that seeks to normalize period-to-period earnings.

This press release contains non-GAAP financial measures within the meaning of Regulation G promulgated by the Securities and Exchange Commission. Pursuant to Regulation G, a reconciliation of these non-GAAP financial measures with the comparable financial measures calculated in accordance with GAAP for the 12 months ended Dec. 31, 2018, and Dec. 31, 2017, is presented in the following Non-GAAP Financial Measures Table.

Additional information regarding Net Element’s results for its year ended Dec. 31, 2018, may be found in Net Element’s annual report on Form 10-K, which was filed with the Security and Exchange Commission (SEC) on April 1, 2019, and may be obtained from the SEC’s Internet website at http://www.sec.gov.

About Net Element

Net Element, Inc. (NASDAQ: NETE) operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the U.S. and selected emerging markets. In the U.S., the Company aims to grow transactional revenue by innovating SME productivity services using blockchain technology solutions and Aptito, our cloud-based, restaurant and retail point-of-sale solution. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500™. In 2017 we were recognized by South Florida Business Journal as one of 2016’s fastest-growing technology companies. Further information is available at www.NetElement.com.

Forward-Looking Statements

Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Net Element and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to the predictability and resilience of the Company’s business model and whether the Company will be successful in achieving further growth and financial improvement. Additional examples of such risks and uncertainties include, but are not limited to (i) Net Element’s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Net Element’s ability to maintain existing, and secure additional, contracts with users of its payment processing services; (iii) Net Element’s ability to successfully expand in existing markets and enter new markets; (iv) Net Element’s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Net Element’s business; (viii) changes in government licensing and regulation that may adversely affect Net Element’s business; (ix) the risk that changes in consumer behavior could adversely affect Net Element’s business; (x) Net Element’s ability to protect its intellectual property; (xi) local, industry and general business and economic conditions; and (xii) adverse effects of potentially deteriorating U.S.-Russia relations, including, without limitation, over a conflict related to Ukraine, including a risk of further U.S. government sanctions or other legal restrictions on U.S. businesses doing business in Russia. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K filed by Net Element with the Securities and Exchange Commission. Net Element anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Net Element assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

NET ELEMENT, INC.

CONSOLIDATED BALANCE SHEETS

NET ELEMENT, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

NET ELEMENT, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

NET ELEMENT, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS

Contact:
Net Element, Inc.
+1 (786) 923-0502
www.netelement.com
media@netelement.com

Corporate Communications:
NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com

$LXRP Launches Its Largest Cannabinoid Research Program

• The R&D program will focus on the proprietary Lexaria DehydraTECH delivery technology with the purpose of enhancing it further
• Results could contribute to new patent filings in the future; in addition, the program will examine more extensively the way DehydraTECH-enabled CBD outperforms generic CBD
• Lexaria-designed nanotech enhancements will also be included in the program

Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is launching its largest cannabinoid research and development program to date. The program consists of 11 separate animal studies, according to a company press release (http://nnw.fm/iY7Tv).

The Lexaria in vitro study design was conceptualized six months ago. Laboratory test articles have been produced and meet or exceed required quality control thresholds. The program has moved on to…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://nnw.fm/LXRP

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$GNPX Provides Full-Year Clinical, Corporate, and Financial Update

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update and the filing of financial results for the year ended December 31, 2018 on Form 10-K with the United States Securities and Exchange Commission.

“Over the past year, we made great progress in advancing the development of our gene therapy platform, including Oncoprex™ immunogene therapy for non-small cell lung cancer,” said Rodney Varner, Chairman and Chief Executive Officer of Genprex. “I’m pleased with our progress and am excited to continue development of our gene therapies for cancer into 2019 and beyond. I’m confident, given all we’ve accomplished in the past year, that 2019 will be a landmark year for Genprex.”

“As we continue to advance our clinical operations and manufacturing programs, Genprex is well positioned to make 2019 a pivotal year,” Julien L. Pham, MD, MPH, President and Chief Operating Officer, stated. “From our successful IPO launch on NASDAQ, to completing a $10 million private placement, we are gaining momentum to reach the important milestones we set for ourselves.”

Clinical Development and Corporate Update

Genprex’s accomplishments for 2018 and early 2019 include:

• Completing its initial public offering and listing of common stock on NASDAQ Capital Market.
• Completing a $10 million private placement.
• Contracting with Accenture to provide clinical data management services to help accelerate the clinical development of Genprex’s lead drug candidate, Oncoprex™.
• Contracting with WIRB-Copernicus Group (WCG) to provide site selection and feasibility services, including Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) oversight for new clinical trial sites that Genprex anticipates adding to participate in its Phase I/II clinical trial evaluating the combination of Oncoprex™ and erlotinib (Tarceva®) in non-small cell lung cancer (NSCLC).
• Selecting 4Clinics as a CRO to provide clinical and regulatory support for Genprex’s clinical development program in the form of biostatistics, statistical programming and analysis, as well as medical and scientific writing for the Phase I/II clinical trial.
• Entering into an agreement with the University of Texas at Austin Dell Medical School to establish executive offices at the school’s Health Discovery Building, joining the WorkSpaces @ Texas Health CoLab.
• Establishing offices in Cambridge, MA, where Dr. Julien Pham, President and COO will oversee the clinical development of Genprex’s lead drug candidate, Oncoprex™.
• Entering into Amendment No. 2 to Clinical Trial Agreement with The University of Texas MD Anderson Cancer Center (MD Anderson) for continued conduct of Phase I/II clinical trial at MD Anderson.
• Entering into a research agreement with MD Anderson for development of a therapeutic approach to treating cancer using TUSC2, the active agent in Genprex’s lead product candidate Oncoprex, in combination with immunotherapies; and for the development and the use of biomarkers to predict patient response to TUSC2 therapy.
• Entering into an agreement with Aldevron, a leading contract manufacturing organization, to supply TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA for use in Genprex’s clinical development program evaluating Oncoprex for the treatment of NSCLC.
• Entering into agreements with additional contract manufacturing organizations to assist with manufacturing scale-up and transfer of manufacturing processes from manufacturing facilities of MD Anderson Cancer Center to commercial facilities.
• Appointing Jan Stevens, RN as Vice President of Clinical Operations, Eric Chapdelaine as Senior Director of Pharmaceutical Sciences and Manufacturing, Kalyn Dabbs as Senior Manager of Communications and Marketing, and John N. Bonfiglio, Ph.D. to Board of Directors.
• Launching a state-of-the-art website and overhauled corporate communications capabilities, including the introduction of a new investors email notification system.

2018 Financial Update

Genprex’s research and development expense was $971,427 for the year ended December 31, 2018, compared to $289,934 for the year ended December 31, 2017. This increase of $681,493 was due to the Company’s focus on improving clinical strategies, expanding research activities, refining existing manufacturing processes, and developing new manufacturing and logistics processes to support future research and development activities. Genprex had a cash position of $8.6 million as of December 31, 2018.

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. Visit the company’s web site at www.genprex.com or follow Genprex on Twitter at twitter.com/genprex, Facebook at facebook.com/genprexinc, and LinkedIn at linkedin.com/company/genprex.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effects of Oncoprex on cancer, alone or in combination with other drugs, our plans to add additional clinical trial sites, our plans to scale-up and transfer our manufacturing processes to commercial facilities, the effect of methods for predicting patients’ response to therapy, the products and services we expect to receive from companies we contract with and the effect of those products and services on the development of Oncoprex™, and statements about our business plans. Risks that contribute to the uncertain nature of the forward-looking statements include: the presence and level of TUSC2’s effect on cancer; the ability of companies we contract with to provide products and services to us, our ability to utilize those products and services, and the effect of those products and services on the development of Oncoprex™; the effect on cancer of combining TUSC2 with immunotherapies or other drugs; the timing, success and cost of our clinical trials and planned clinical trials of TUSC2 and Oncoprex and other potential product candidates; the timing and success of obtaining FDA approval of Oncoprex and our other potential product candidates; the success, cost and timing of our product candidate development activities; our ability to execute on our strategy; regulatory developments in the United States and foreign countries; and our estimates regarding expenses, future revenue and capital requirements. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190401005248/en/

$RIV.V $RIV $CNOPF Portfolio Company Awarded Second Licence From Health Canada

TORONTO, April 1, 2019 – Canopy Rivers Inc. (“Canopy Rivers” or the “Company”) (TSXV: RIV) is pleased to share that its portfolio company, James E. Wagner Cultivation Corporation (“JWC“) (TSXV: JWCA) (OTCQX: JWCAF), has received its cultivation licence from Health Canada for its Kitchener-based commercial scale production facility (“JWC2“). This second licence launches the initial phase of JWC2, a 345,000 square foot production and distribution complex where JWC is rolling out more than 130 individual production rooms utilizing JWC’s proprietary GrowthSTORM™ Dual Droplet cultivation platform and methodologies. With the newly licenced facility located just minutes from JWC’s already licenced pilot facility, JWC is well-positioned for an efficient ramp-up and expects to commence cannabis production at JWC2 immediately.

“While optimizing production methodologies at their already licenced pilot facility, JWC has concurrently built out and implemented refinements and learnings for production at commercial scale,” said Daniel Pearlstein, EVP, Strategy, of Canopy Rivers. “We are pleased to see Health Canada reward JWC for the quality of their operations, and their disciplined approach to expansion with the issuance of this second site licence.”

Canopy Rivers believes that JWC’s multigenerational cannabis and hemp experience, its unique and proprietary production methodologies, and its disciplined and de-risked path to scale makes JWC a strong constituent within the Canopy Rivers ecosystem. After making its initial investment in 2017, the Company has continued to support JWC and currently holds approximately 13% of the issued and outstanding common shares in the capital of JWC on a fully-diluted basis. Additionally, Canopy Rivers receives a long-term royalty cash flow stream from JWC with a minimum annual payment of approximately $488,000. The royalty has a term of 20 years.

“We have seen strong demand for standardized, quality-controlled indoor cannabis within both the medical and adult use cannabis markets,” continued Pearlstein. “Until now, JWC has focused on delivering an exceptional experience to a concentrated population of patients and through Canopy Growth’s Spectrum Cannabis online store. With this second site licence in hand and the expanded production facility now online, JWC is well-positioned to bring their premium quality-controlled cannabis products to patient and consumer markets on a much larger scale.”

For more information regarding the Company’s investment in JWC, please refer to the joint management information circular of Canopy Rivers Corporation and the Company dated August 8, 2018, filed with Canadian securities regulators and available on the Company’s profile on SEDAR at www.sedar.com. For additional information about JWC, please refer to JWC’s profile on SEDAR or their website at www.jwc.ca.

About Canopy Rivers:

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers works collaboratively with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) to identify strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem.

Forward-Looking Statements

This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Canopy Rivers with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding: the strength of JWC in the Canopy Rivers ecosystem; JWC’s ability to bring their cannabis products to patient and consumer markets on a much larger scale; and other expectations for other economic, business, and/or competitive factors.

Investors are cautioned that forward-looking information is not based on historical facts but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Canopy Rivers believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of Canopy Rivers. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: regulatory and licensing risks; JWC’s ability to cultivate cannabis at scale; the ability of JWC to obtain a licence to sell cannabis under applicable legislation in Canada; the ability to secure distribution and sales channels; changes in general economic, business and political conditions, including changes in the financial markets; the global regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; and the risk factors set out in Canopy Rivers’ final short form prospectus dated February 21, 2019, filed with Canadian securities regulators and available on Canopy Rivers’ profile on SEDAR at www.sedar.com.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Canopy Rivers has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Canopy Rivers does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.